Skip to main content
Log in

Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

In this study, the Gαqi5 protein was used to force the human nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor to signal through the Ca2+ pathway in CHO cells. [Ca2+]i levels were monitored using the fluorometer FlexStation II and the Ca2+ dye Fluo 4 AM. Concentration response curves were generated with a panel of full and partial agonists, while NOP antagonists were assessed in inhibition-response curves. The following rank order of potency of antagonists was measured: \({\text{SB}} - {\text{612111}} >{\text{J}} - 113397 = {\text{Trap}} - 101 \geqslant {\text{UFP}} - 101 >\left[ {{\text{Nphe}}^{\text{1}} } \right]{{\text{N}} \mathord{\left/ {\vphantom {{\text{N}} {{\text{OFQ}}}}} \right. \kern-\nulldelimiterspace} {{\text{OFQ}}}}\left( {1 - 13} \right){\text{NH}}_{\text{2}} >>\) naloxone, which is superimposable to literature findings. The rank order of potency of full and partial agonists is also similar to that obtained in previous studies with the exception of a panel of ligands (UFP-112, Ro 64-6198, ZP120, UFP-113) whose potency was relatively low in the Gαqi5–NOP receptor calcium assay. Interestingly, these NOP ligands are characterized by slow kinetic of interaction with the NOP receptor, as demonstrated by bioassay experiments. These results demonstrated that the FlexStation II–Gαqi5–NOP receptor calcium assay represents an adequate and useful screening for NOP receptor ligands, particularly for antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Arduin M, Spagnolo B, Calo G et al (2007) Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. Bioorg Med Chem 15:4434–4443

    Article  PubMed  CAS  Google Scholar 

  • Berger H, Calo G, Albrecht E et al (2000) [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain. J Pharmacol Exp Ther 294:428–433

    PubMed  CAS  Google Scholar 

  • Bigoni R, Calo G, Rizzi A et al (2000) In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 361:565–568

    Article  PubMed  CAS  Google Scholar 

  • Butour JL, Moisand C, Mollereau C et al (1998) [Phe1psi(CH2–NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor. Eur J Pharmacol 349:R5–R6

    Article  PubMed  CAS  Google Scholar 

  • Calo G, Rizzi A, Bogoni G et al (1996) The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 311:R3–R5

    Article  PubMed  CAS  Google Scholar 

  • Calo G, Guerrini R, Bigoni R et al (2000a) Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol 129:1183–1193

    Article  PubMed  CAS  Google Scholar 

  • Calo G, Guerrini R, Rizzi A et al (2000b) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129:1261–1283

    Article  PubMed  CAS  Google Scholar 

  • Calo G, Rizzi A, Rizzi D et al (2002) [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136:303–311

    Article  PubMed  CAS  Google Scholar 

  • Calo G, Guerrini R, Rizzi A et al (2005) UFP-101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Drug Rev 11:97–112

    PubMed  CAS  Google Scholar 

  • Carra G, Rizzi A, Guerrini R et al (2005) [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther 312:1114–1123

    Article  PubMed  CAS  Google Scholar 

  • Chiou LC, Liao YY, Fan PC et al (2007) Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets. 8:117–135

    Article  PubMed  CAS  Google Scholar 

  • Conklin BR, Farfel Z, Lustig KD et al (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature May 20 363(6426):274–276

    Article  CAS  Google Scholar 

  • Coward P, Chan SD, Wada HG et al (1999) Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal Biochem 270:242–248

    Article  PubMed  CAS  Google Scholar 

  • De Risi C, Piero Pollini G et al (2001) A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dih ydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist. Bioorg Med Chem. 9:1871–1877

    Article  PubMed  Google Scholar 

  • Dooley CT, Spaeth CG, Berzetei-Gurske IP et al (1997) Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 283:735–741

    PubMed  CAS  Google Scholar 

  • Guerrini R, Calo G, Rizzi A et al (1997) Address and message sequences for the nociceptin receptor: a structure–activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40:1789–1793

    Article  PubMed  CAS  Google Scholar 

  • Guerrini R, Calo G, Rizzi A et al (1998) A new selective antagonist of the nociceptin receptor. Br J Pharmacol 123:163–165

    Article  PubMed  CAS  Google Scholar 

  • Guerrini R, Carra G, Calo G et al (2004) Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity. J Pept Res 63:477–484

    Article  PubMed  CAS  Google Scholar 

  • Gunduz O, Rizzi A, Baldisserotto A et al (2006) In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. Eur J Pharmacol. 539:39–48

    Article  PubMed  Google Scholar 

  • Hashiba E, Lambert DG, Jenck F et al (2002) Characterisation of the non-peptide nociceptin receptor agonist, Ro64-6198 in Chinese hamster ovary cells expressing recombinant human nociceptin receptors. Life Sci 70:1719–1725

    Article  PubMed  CAS  Google Scholar 

  • Jenck F, Wichmann J, Dautzenberg FM et al (2000) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci USA 97:4938–4943

    Article  PubMed  CAS  Google Scholar 

  • Kapusta DR, Thorkildsen C, Kenigs VA et al (2005) Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium–potassium-sparing aquaretic activity. J Pharmacol Exp Ther 314:652–660

    Article  PubMed  CAS  Google Scholar 

  • Kenakin T (2004) A Pharmacology Primer. Elsevier Academic, San Diego

    Google Scholar 

  • Kocsis L, Orosz G, Magyar A et al (2004) Nociceptin antagonism: probing the receptor by N-acetyl oligopeptides. Regul Pept 122:199–207

    Article  PubMed  CAS  Google Scholar 

  • Kostenis E, Waelbroeck M, Milligan G (2005) Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol Sci. 26:595–602

    Article  PubMed  CAS  Google Scholar 

  • Lambert DG (2008) The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nature Reviews Drug Discovery 7:694–710

    Article  PubMed  CAS  Google Scholar 

  • Mason SL, Ho M, Nicholson J et al (2001) In vitro characterization of Ac-RYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors. Neuropeptides 35:244–256

    Article  PubMed  CAS  Google Scholar 

  • McDonald J, Barnes TA, Okawa H et al (2003a) Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol 140:61–70

    Article  PubMed  CAS  Google Scholar 

  • McDonald J, Calo G, Guerrini R et al (2003b) UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies. Naunyn Schmiedebergs Arch Pharmacol 367:183–187

    Article  PubMed  CAS  Google Scholar 

  • Meunier JC, Mollereau C, Toll L et al (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532–535

    Article  PubMed  CAS  Google Scholar 

  • Molinari P, Casella I, Costa T (2008) Functional complementation of high-efficiency resonance energy transfer: a new tool for the study of protein binding interactions in living cells. Biochem J. 409:251–261

    Article  PubMed  CAS  Google Scholar 

  • Ozaki S, Kawamoto H, Itoh Y et al (2000) In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45–53

    Article  PubMed  CAS  Google Scholar 

  • Reinscheid RK, Nothacker HP, Bourson A et al (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792–794

    Article  PubMed  CAS  Google Scholar 

  • Rizzi D, Bigoni R, Rizzi A et al (2001) Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol 363:551–555

    Article  PubMed  CAS  Google Scholar 

  • Rizzi A, Rizzi D, Marzola G et al (2002) Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice. Br J Pharmacol 137:369–374

    Article  PubMed  CAS  Google Scholar 

  • Rizzi A, Spagnolo B, Wainford RD et al (2007) In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides. 28:1240–1251

    Article  PubMed  CAS  Google Scholar 

  • Shoblock JR (2007) The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev. 13:107–136

    Article  PubMed  CAS  Google Scholar 

  • Spagnolo B, Carra G, Fantin M et al (2007) Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(−)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: in Vitro Studies. J Pharmacol Exp Ther 321:961–967

    Article  PubMed  CAS  Google Scholar 

  • Thomsen C, Valsborg JS, Platou J et al (2000) [3H]ac-RYYRWK-NH2, a novel specific radioligand for the nociceptin/orphanin FQ receptor. Naunyn Schmiedebergs Arch Pharmacol 362:538–545

    Article  PubMed  CAS  Google Scholar 

  • Trapella C, Guerrini R, Piccagli L et al (2006) Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 14:692–704

    Article  PubMed  CAS  Google Scholar 

  • Zaratin PF, Petrone G, Sbacchi M et al (2004) Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (−)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 308:454–461

    Article  PubMed  CAS  Google Scholar 

  • Zaveri N (2003) Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 73:663–678

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by funds from the University of Ferrara (FAR grant to GC and SS) and from the Italian Ministry of University (PRIN 2006 grant to DR).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Girolamo Calo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camarda, V., Fischetti, C., Anzellotti, N. et al. Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 . Naunyn-Schmied Arch Pharmacol 379, 599–607 (2009). https://doi.org/10.1007/s00210-009-0396-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-009-0396-x

Keywords

Navigation